Article
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
European journal of medicinal chemistry - 5 Sept 2023
Wang Qing-Xin, Zhang Peng-Yu, Li Qing-Qing, Tong Zhen-Jiang, Wu Jia-Zhen, Yu Shao-Peng, Yu Yan-Cheng, Ding Ning, Leng Xue-Jiao, Chang Liang, Xu Jin-Guo, Sun Shan-Liang, Yang Ye, Li Nian-Guang, Shi Zhi-Hao
Abstract excerpt
Glioma is one of the most common types of brain tumors, and its high recurrence and mortality rates threaten human health. In 2008, the frequent isocitrate dehydrogenase 1 (IDH1) mutations in glioma were reported, which brought a new strategy in the treatment of this challenging disease. In this perspective, we first discuss the possible gliomagenesis after IDH1 mutations (mIDH1). Subsequently, we systematically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.